Immatics N.V.
NASDAQ:IMTXBiotechnology
+$0.15 today
- Market cap
- $912.78M
- Beta
- 1.30
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$1.59
Volume 1.57M
Average 0.46M
IMTX Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Immatics N.V.NASDAQ: IMTX
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -€51.32M, compared with €6.1M a year earlier. Trailing-twelve-month net change in cash was €51.59M. Over 3 fiscal years it compounded at +106.7% a year.
Context
- Net change in cash amounted to 284.1% of revenue in FY2025, up 272.4 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -€51.32M or moves back toward the trailing-twelve-month quarterly average of €12.9M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
EUR · from the cash flow
- Latest · FY2025
- 137.12M EUR
- Year-over-year change
- +650.3%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 137.12M | +650.3% |
| FY2024 | 2024-12-31 | 18.28M | -73.9% |
| FY2023 | 2023-12-31 | 69.95M | +350.6% |
| FY2022 | 2022-12-31 | 15.53M | +120.8% |
| FY2021 | 2021-12-31 | (74.54M) | — |
Net Change in Cash vs competitors
How IMTX compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -57.3% is the 5th highest of 11, against a peer median of -78.9%.
- Net change in cash amounts to 138.3% of revenue for IMTX, versus a peer median of 49.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €774.56M EUR | -183.0% | — | 29.3% | |
| LTM Sep 2026 | $181.76M USD | +200.8% | +85.0% | 13.4% | |
| LTM Mar 2026 | $94.68M USD | -2129.6% | -4.8% | 139.1% | |
| LTM Mar 2026 | €51.59M EUR | -57.3% | +106.7% | 138.3% | |
| LTM Mar 2026 | $29.66M USD | +457.2% | -35.6% | 95683.9% | |
| LTM Mar 2026 | $26.05M USD | -291.6% | -14.0% | 285.1% | |
| LTM Mar 2026 | $24.17M USD | -93.2% | -52.2% | 6.3% | |
| LTM Mar 2026 | $22.28M USD | +158.7% | -14.5% | 49.4% | |
| LTM Mar 2026 | $21.92M USD | -84.2% | — | 101.4% | |
| LTM Mar 2026 | $12.15M USD | +41.5% | -40.4% | — | |
| LTM Mar 2026 | $5.63M USD | -73.5% | +5.1% | 24.3% | |
| Peer median (excluding IMTX) | — | -78.9% | -14.3% | 49.4% | |
Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.34M) | 37.51M | (94.65M) | 15.22M | (188.69M) |
| Depreciation & Amortization | 5.26M | 6.97M | 7.23M | 12.23M | 11.91M |
| Deferred Income Tax | 11.15M | 4.52M | 0 | 6.13M | 0 |
| Stock-Based Compensation | 26.4M | 22.57M | 20.71M | 17.64M | 0 |
| Change in Working Capital | (31.7M) | 37.26M | 81.63M | (163.88M) | (42.23M) |
| Accounts Receivables | 569K | (429K) | (2.98M) | (1.76M) | (232.45K) |
| Inventory | 0 | 0 | (84.24M) | 0 | 0 |
| Accounts Payables | (31.78M) | 45.56M | 84.24M | 0 | (36.13M) |
| Other Working Capital | (483K) | (7.87M) | 84.61M | (162.11M) | (5.87M) |
| Other Non-Cash Items | 433K | (8.7M) | 3.31M | (45.37M) | 49.36M |
| Operating Cash Flow | (81.78M) | 100.13M | 18.23M | (158.03M) | (169.66M) |
| Capital Expenditures | (5.66M) | (6.22M) | (30.96M) | (16.48M) | (6.3M) |
| Acquisitions (Net) | 551K | (199.91M) | 0 | 0 | 0 |
| Purchases of Investments | (11.3M) | (216.32M) | (415.33M) | (450.35M) | (324.92M) |
| Sales of Investments | 24.45M | 12.7M | 414.74M | 314.44M | 528.16M |
| Other Investing Activities | (551K) | 199.96M | (8K) | (206K) | 0 |
| Investing Cash Flow | 7.49M | (209.79M) | (31.39M) | (152.39M) | 196.7M |
| Debt Repayment | (2.71M) | (2.84M) | (3.85M) | (2.01M) | 0 |
| Common Stock Issued | 94K | 134.48M | 90.4M | 343.01M | 96.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (7.93M) | (2.04M) | (21.31M) | (2.84M) |
| Financing Cash Flow | (2.61M) | 123.71M | 84.52M | 319.68M | 93.51M |
| Effect of Forex Changes | 2.37M | 1.48M | (1.4M) | 9.01M | 16.56M |
| Net Change in Cash | (74.54M) | 15.53M | 69.95M | 18.28M | 137.12M |
| Free Cash Flow | (87.44M) | 93.92M | (12.73M) | (174.51M) | (175.95M) |
Immatics N.V.
NASDAQ:IMTX
Intrinsic Alpha fair value
Locked
Current Price
$6.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.